NEWS & INSIGHTS

Emna Makhlouf, Chief of Staff: "Working with cancer survivors gives a lot of purpose to what we do"

Inside Cure51

The science

Publication Date:
TO READ NEXT

TechBio vs Biotech: What's the Difference? (Complete Guide)

In the last episode of Agathe Lecaron's podcast Ex-Vitro, our Chief of Staff Emna Makhlouf shares why our scientific approach feels positive.
A huge thank you to Agathe Lecaron for welcoming us on her podcast!

Emna Makhlouf, Chief of Staff


Updated: May 5, 2026

Table of Contents
in THIS ARTICLE
In this article

EMNA MAKHLOUF

Chief of Staff

MORE ARTICLES IN THIS TOPIC
RELATED ARTICLES
computational-biology-team-cure51-nick-riddiford

From Complex Data to Scientific Insight: Inside Cure51’s Computational Biology Team

computational-biology-team-cure51-nick-riddiford

From Complex Data to Scientific Insight: Inside Cure51’s Computational Biology Team

sfp-cure51-pancreatic-cancer copy

Cure51 at the SFP Congress: What Exceptional Pancreatic Cancer Survival Can Teach Us About Pancreatic Cancer

sfp-cure51-pancreatic-cancer copy

Cure51 at the SFP Congress: What Exceptional Pancreatic Cancer Survival Can Teach Us About Pancreatic Cancer

Nicolas-Wolikow-Cure51-Servier-Partnership-Glioblastoma

Our CEO Nicolas Wolikow: "Our New Partnership with Servier Reflects Our Unique Approach to Glioblastoma Research"

Nicolas-Wolikow-Cure51-Servier-Partnership-Glioblastoma

Our CEO Nicolas Wolikow: "Our New Partnership with Servier Reflects Our Unique Approach to Glioblastoma Research"

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

Explore more

Ashley-Lakner-cure51-servier

ASHLEY LAKNER, CSO: “OUR PARTNERSHIP WITH SERVIER OPENS NEW OPPORTUNITIES TO IDENTIFY THERAPEUTIC TARGETS FOR GLIOBLASTOMA”

READ MORE

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

Explore more

Ashley-Lakner-cure51-servier

ASHLEY LAKNER, CSO: “OUR PARTNERSHIP WITH SERVIER OPENS NEW OPPORTUNITIES TO IDENTIFY THERAPEUTIC TARGETS FOR GLIOBLASTOMA”

READ MORE

OUR TOP STORIES

NEWS & INSIGHTS

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

Explore more

Ashley-Lakner-cure51-servier

ASHLEY LAKNER, CSO: “OUR PARTNERSHIP WITH SERVIER OPENS NEW OPPORTUNITIES TO IDENTIFY THERAPEUTIC TARGETS FOR GLIOBLASTOMA”

READ MORE

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

Contact us

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

Contact us

Contact us

ROSALIND

Contact us